Efficacy

Tabrecta (capmatinib) for Lung Cancer

Tabrecta (capmatinib) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). Tabrecta is specifically indicated for patients whose tumors have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test. The efficacy of Tabrecta was demonstrated in a clinical trial that showed a significant reduction in tumor size for a substantial proportion of patients with this specific genetic alteration.

The clinical trial that led to the approval of Tabrecta included patients with metastatic NSCLC with MET exon 14 skipping mutations. The results showed an overall response rate (ORR) of 68% in newly diagnosed patients and 41% in previously treated patients. These response rates indicate that Tabrecta can be an effective treatment option for patients with this specific type of lung cancer, offering hope for improved outcomes.

Vegzelma (bevacizumab-adcd) for Lung Cancer

Vegzelma (bevacizumab-adcd) is a biosimilar to the original biologic drug Avastin (bevacizumab) and is used in the treatment of various types of cancer, including NSCLC. Bevacizumab is a monoclonal antibody that works by inhibiting vascular endothelial growth factor (VEGF), thereby reducing the blood supply to tumors and limiting their growth. As a biosimilar, Vegzelma has been shown to have no clinically meaningful differences in terms of safety, purity, and potency in comparison to its reference product, Avastin.

In the context of NSCLC, bevacizumab, and by extension Vegzelma, is typically used in combination with chemotherapy. Clinical trials have demonstrated that adding bevacizumab to chemotherapy can extend the time before the cancer worsens (progression-free survival) and can also improve overall survival in some patients with advanced non-squamous NSCLC. The efficacy of Vegzelma as a biosimilar suggests that it can be used interchangeably with bevacizumab, providing a potentially more cost-effective option for patients requiring this type of targeted therapy.